Formula I Kinase Inhibitors for Selective B-Raf V600E Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with protein kinase activity modulation are inadequate, as existing compounds lack specificity and efficacy in targeting various kinase types, including Raf protein kinases, which are often mutated in cancers.
Innovation Solution
Development of compounds, specifically those of Formula I, which are active on a wide range of protein kinases, including Raf kinases, with structures that allow for selective inhibition of mutated forms like B-Raf V600E, offering therapeutic benefits by modulating kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used to treat protein kinase-mediated diseases, then treatment is provided, but the compounds lack specificity and efficacy in targeting various kinase types including Raf protein kinases
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters of the compound structure (Formula I) including substituent groups (R1-R4), linkers (L1-L3), and heteroaryl moieties (Ar) to optimize binding affinity and specificity for mutated Raf kinases. This structural parameter optimization enables selective inhibition of B-Raf V600E with IC50 values below 1 nM while maintaining activity against other kinase types.
Solution Approach 2:
The patent implements local quality by designing specific molecular regions within Formula I compounds that interact with particular residues in the ATP-binding pocket of mutated Raf kinases. The heteroaryl group (Ar) and its substituents (R1) are positioned to form specific interactions with mutated residues, providing localized selective inhibition while the rest of the molecule maintains general kinase binding capability.
2Reliability
If compounds are designed for high specificity to mutated kinases, then selective inhibition is achieved, but the structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the compound structure into distinct functional modules: a heteroaryl core (Ar) for specific recognition, substituent groups (R1-R4) for affinity modulation, and linker regions (L1-L3) for structural flexibility. This modular segmentation allows systematic optimization of specificity without overwhelming complexity, as each module can be independently tuned.
Solution Approach 2:
The patent implements universality by designing the core structure of Formula I to serve multiple functions: the heteroaryl group provides specific recognition of mutated residues, the substituent patterns enable binding to various kinase types, and the linker regions accommodate different spatial requirements. This multi-functional design achieves selective inhibition across multiple kinase targets without requiring entirely different molecular scaffolds for each target.
Data Source
AI summary
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.